Arcturus Therapeutics Holdings (ARCT) Cash from Financing Activities (2018 - 2026)

Arcturus Therapeutics Holdings' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $16000.0 for Q1 2026.

• Quarterly Cash from Financing Activities fell 99.89% year-over-year to $16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 million (down 109.75% YoY) and the FY2025 annual result came in at $13.4 million, up 146.99% from the prior year.
• Cash from Financing Activities was $16000.0 for Q1 2026 at Arcturus Therapeutics Holdings, down from $11.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $21.8 million in Q3 2023 and bottomed at -$27.4 million in Q1 2023.
• A 5-year average of -$478235.3 and a median of $257000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 8244.05% — and 2025, when it soared 8622.39%.
• Arcturus Therapeutics Holdings' Cash from Financing Activities stood at -$2.2 million in 2022, then plunged by 735.89% to -$18.7 million in 2023, then surged by 100.72% to $134000.0 in 2024, then surged by 8622.39% to $11.7 million in 2025, then plunged by 99.86% to $16000.0 in 2026.
• Business Quant data shows ARCT's Cash from Financing Activities at $16000.0 in Q1 2026, $11.7 million in Q4 2025, and $1.2 million in Q3 2025.